Small molecule · Cytotoxic · developed by Alaunos Therapeutics
Darinaparsin is a small-molecule organic arsenical that generates cytotoxic arsenic compounds when glutathione concentrations are low. It disrupts mitochondrial bioenergetics and produces reactive oxygen species to induce tumor cell apoptosis, while potentially interrupting G2/M cell cycle progression and exhibiting antiangiogenic effects. It is studied in multiple myeloma, lymphomas, and solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00423644 | Phase 2 | Multiple Myeloma | Completed | TCRT |
| NCT00421213 | Phase 2 | Hematologic Neoplasms | Terminated | TCRT |
| NCT00303199 | Phase 1/2 | Multiple Myeloma | Completed | TCRT |
| NCT00592163 | Phase 1 | Advanced Solid Tumors | Completed | TCRT |
| NCT00509782 | Phase 1 | Solid Tumors | Completed | TCRT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorsBone Marrow NeoplasmsHematologic NeoplasmsLymphomasMultiple MyelomaNon-Hodgkin's LymphomaSolid Tumors
Updated Oct 3, 2026. Something wrong or missing? Report it on the TCRT page.
See TCRT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TCRT catalysts and pipeline →